Moderna shares rose 13% to a year-to-date high as R&D positives were released ahead of earnings
November 5, Moderna's stock price closed up approximately 13.1%, with progress in its research and development projects drawing attention. On Hyperliquid, the MRNA contract price, trading volume, and open interest value all rose simultaneously.